Cargando…

Alzheimer's disease drug development pipeline: 2023

INTRODUCTION: Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. METHODS: We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey, Zhou, Yadi, Lee, Garam, Zhong, Kate, Fonseca, Jorge, Cheng, Feixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210334/ https://www.ncbi.nlm.nih.gov/pubmed/37251912 http://dx.doi.org/10.1002/trc2.12385

Ejemplares similares

Alzheimer's disease drug development pipeline: 2021
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2022
por: Cummings, Jeffrey, et al.
Publicado: (2022)

Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2020)

Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2023)

Erratum: Alzheimer's disease drug development pipeline: 2023
Publicado: (2023)

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
por: Cummings, Jeffrey L, et al.
Publicado: (2014)

Who funds Alzheimer's disease drug development?
por: Cummings, Jeffrey, et al.
Publicado: (2021)

The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease
por: Zhou, Yadi, et al.
Publicado: (2022)

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
por: Zhou, Yadi, et al.
Publicado: (2021)

Alzheimer’s Disease Drug Development Pipeline 2020
por: Sabbagh, M.N.
Publicado: (2020)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Artificial intelligence in COVID-19 drug repurposing
por: Zhou, Yadi, et al.
Publicado: (2020)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023)

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
por: Fang, Jiansong, et al.
Publicado: (2022)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease
por: Xu, Jielin, et al.
Publicado: (2021)

Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
por: Huang, Li-Kai, et al.
Publicado: (2023)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease
por: Xu, Jielin, et al.
Publicado: (2022)

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
por: Cummings, Jeffrey, et al.
Publicado: (2018)

The role of basket trials in drug development for neurodegenerative disorders
por: Cummings, Jeffrey, et al.
Publicado: (2022)

The price of progress: Funding and financing Alzheimer's disease drug development
por: Cummings, Jeffrey, et al.
Publicado: (2018)

The Alzheimer’s disease drug development landscape
por: van Bokhoven, Pieter, et al.
Publicado: (2021)

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
por: Denis, Agathe, et al.
Publicado: (2023)

Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
por: Cummings, Jeffrey L., et al.
Publicado: (2023)

Advances in the Cystic Fibrosis Drug Development Pipeline
por: Esposito, Christine, et al.
Publicado: (2023)

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
por: Zhou, Yadi, et al.
Publicado: (2020)

Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
por: Yadollahikhales, Golnaz, et al.
Publicado: (2023)

Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis
por: Van de Roovaart, Hannah J., et al.
Publicado: (2023)

The development of an automated machine learning pipeline for the detection of Alzheimer’s Disease
por: Chedid, Nicholas, et al.
Publicado: (2022)

What’s in the pipeline? Drugs in development for autism spectrum disorder
por: Sung, Min, et al.
Publicado: (2014)

Alzheimer's disease diagnostic criteria: practical applications
por: Cummings, Jeffrey
Publicado: (2012)

New approaches to symptomatic treatments for Alzheimer’s disease
por: Cummings, Jeffrey
Publicado: (2021)

Antiepileptic drugs in development pipeline: A recent update
por: Kaur, Harjeet, et al.
Publicado: (2016)

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
por: Cummings, Jeffrey
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g42itkd6biivdcv9kihf75ng4t